A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

November 30, 2010

Conditions
Tuberculosis
Interventions
BIOLOGICAL

Placebo

This is the identical buffer solution in which AERAS-402 is formulated. The placebo (1.0 mL volume) was administered by intramuscular (IM) injection to the deltoid area on Study Day 0 for groups 1 and 2 and Study Day 0 and 42 for group 3.

BIOLOGICAL

AERAS-402 3 x 10^8 vp

AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0

BIOLOGICAL

AERAS-402 3 x 10^9 vp

AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0

BIOLOGICAL

AERAS-402 3 x 10^10 vp

AERAS-402 was administered by intramuscular (IM) injection to the deltoid area on Study Days 0 and 42.

Trial Locations (1)

7700

University of Cape Town Lung Institute Pty (Ltd), Cape Town

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Crucell Holland BV

INDUSTRY

lead

Aeras

OTHER